• AlzeCure gets an abstract on phase II clinical data with ACD440 for neuropathic pain accepted at pain conference

  • AlzeCure presents positive phase II clinical data with ACD440 against neuropathic pain at EFIC 2023 Conference

  • AlzeCure gets presentation accepted on disease-modifying effects of ACD856 at Alzheimer’s conference

AlzeCure Pharma

AlzeCure Pharma is a Swedish pharmaceutical company focusing on the research and development of innovative and efficacious treatments for Alzheimer’s disease and related disorders

Research

AlzeCure is developing disease modifying and symptomatic first in class treatments for Alzheimer’s disease and other conditions characterized by cognitive dysfunction

Alzheimer’s Disease

Alzheimer’s disease is a deadly disorder which lacks effective treatments. The need for novel treatments is therefore urgent.